Biovie is trading 34.33% up at $1.80 after renewed attention to positive Phase 2 SUNRISE-PD results for bezisterim.
- The trial reportedly met its primary endpoint, showing statistically significant motor, non-motor, and biomarker improvements with placebo-like safety.
- Coverage highlighted a new passive beneficial-ownership filing, adding investor interest.
- The broader biotech sector is down, making Biovie’s company-specific catalyst especially prominent.